Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022. Read More
At first blush, to say that depression occurs with other diseases may seem like belaboring the obvious. After all, to put it in the bluntest possible terms, it’s sad to be sick. But by looking more closely, it soon becomes clear that the association is stronger than that. The strongest association between depression and other diseases, Stefan Gold told the audience at the European College of Neuropsychopharmacology (ECNP) annual conference in Vienna this week, is “not necessarily the most severe or most immediately life-threatening disorders… [it’s] across the spectrum." Read More
C2orf82, also known as small novel rich in cartilage (SNORC), is a gene located on chromosome 2 that is known to play a role in chondrocyte maturation. Read More
Sumitomo Pharma Oncology Inc. has patented (furopyrimidin-4-yl)piperazine compounds acting as DNA repair protein RAD51 homolog 1 (RAD51) expression inhibitors reported to be useful for the treatment of cancer. Read More
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University. Read More
Cadent Therapeutics Inc. and Novartis AG have described cyclopental[c]pyrrol glutamate receptor ionotropic, NMDA 2B (GRIN2B; GluN2B) negative allosteric modulators reported to be useful for the treatment of pain, autism, tinnitus, anxiety disorders, Rett syndrome, Parkinson's disease, migraine and major depression. Read More
Columbia University has presented non-hallucinogenic ariadne analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, among other disorders. Read More
Domain Therapeutics SA has received clinical trial application (CTA) clearances in France and Belgium for its immuno-oncology program DT-9081, allowing the initiation of a phase I trial for solid tumors. Read More
Bioage Labs Inc. has synthesized new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndromes, hearing loss, Ménière's disease, tinnitus, vertigo and inflammatory disorders. Read More
Additional early-stage research and drug discovery news in brief, from: Enanta, Hemostemix, Iecure, Inmune, Kalvista, Surface Oncology, Precerv, Qualigen. Read More
